Status:

COMPLETED

A Pilot Study of rhBMP-2/ACS With the INTERFIX™ Device for the AnteriorLumbar Interbody Fusion in Patients With Degenerative Disc Disease

Lead Sponsor:

Medtronic Spinal and Biologics

Conditions:

Degenerative Disc Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this pilot clinical trial is to evaluate the device design as a method of facilitating spinal fusion.

Eligibility Criteria

Inclusion

  • Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history (e.g., pain \[leg, back, or symptoms in the sciatic nerve distribution\], function deficit and/or neurological deficit) and radiographic studies (e.g., CT, MRI, X-Ray, etc.) to include one or more of the following:
  • instability (defined as angular motion \>= 5° and/or translation \>= 4mm, based on Flex/Ext radiographs);
  • osteophyte formation;
  • decreased disc height;
  • thickening of ligamentous tissue;
  • disc degeneration or herniation; and/or
  • facet joint degeneration.
  • Has preoperative Oswestry score \>= 35.
  • Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).
  • Has single-level symptomatic degenerative involvement from L2 to S1.
  • Is at least 18 years of age, inclusive, at the time of surgery.
  • Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
  • If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
  • Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion

  • Had previous anterior spinal fusion surgical procedure at the involved level.
  • Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.
  • Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
  • Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  • Has presence of active malignancy.
  • Has overt or active bacterial infection, either local or systemic.
  • Is grossly obese, i.e., weight\> 40% over ideal for their age and height.
  • Has fever (temperature\> 101°F oral) at the time of surgery.
  • Has a documented titanium alloy allergy or intolerance.
  • Is mentally incompetent. If questionable, obtain psychiatric consult.
  • Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
  • Is a prisoner.
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
  • Is a tobacco user at the time of surgery.
  • Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
  • Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
  • Has a history of exposure to injectable collagen implants.
  • Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
  • Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
  • Has received any previous exposure to any/all BMP of either human or animal extraction.
  • Has a history of allergy to bovine products or a history of anaphylaxis.
  • Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).

Key Trial Info

Start Date :

February 1 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2003

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT01491451

Start Date

February 1 1999

End Date

January 1 2003

Last Update

May 17 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.